What type of study is this?

September 12, 2025

Figure 4 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas

Key Points

Significant ADCC was observed only in TROP2-positive endometrial cancer cell lines.
Evaluated three endometrial cancer cell lines, with ADCC measured in the presence of PBMCs.
Datopotamab deruxtecan demonstrates potential as an effective treatment for TROP2-targeted endometrial cancers.
Results indicate the importance of TROP2 expression for the efficacy of antibody-drug conjugates.

Abstract

ADCC results of Dato-DXd, CTL-ADC, datopotamab, and rituximab (anti-CD20) in three representative endometrial cancer cell lines (A) END(K)34 TROP2-negative cell line, (B) END(K)254 TROP2 3+ cell line, and (C) END(K)265 TROP2 3+ cell line in the presence of PBMCs. Significant ADCC was detectable only against the TROP2-positive cell lines (B and C; *, P

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Niccolò G. Santin

Namrata Sethi

Stefania Bellone

Actions

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Figure 4 from Preclinical Activity of Datopotamab Deruxtecan (Dato-DXd), an Antibody–Drug Conjugate Targeting TROP2, in Poorly Differentiated Endometrial Carcinomas

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Actions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider